AUS
NZ
UK
CA
USA
IND
_06_16_2026_04_54_27_535266.jpg)
Investors in the Australian Securities Exchange (ASX) often seek out blue-chip shares known for their stability, strong business models, and positive growth outlooks. Two such blue-chip shares that analysts are tipping for strong returns over the next 12 months are ResMed Inc (ASX:RMD) and Treasury Wine Estates Ltd (ASX:TWE).
- ResMed Inc (ASX: RMD):
ResMed, a global leader in sleep technology and respiratory medicine, experienced a recent selloff that analysts believe has created an enticing buying opportunity. According to Goldman Sachs, the perceived downside risk from GLP-1/GIPs (glucagon-like peptide-1/glucose-dependent insulinotropic peptide) has been overcapitalized in ResMed's current valuation, presenting an asymmetric upside risk at current levels.
Goldman Sachs recently reiterated its "Buy" rating on ResMed with a $32.00 price target. This target suggests a potential upside of 26% for investors over the next 12 months. The analysts acknowledge the recent selloff but believe that the market has overemphasized the risks associated with GLP-1/GIPs.
ResMed's diversified portfolio in sleep and respiratory solutions positions it well for sustained growth. The company's commitment to innovation and addressing key healthcare challenges contributes to its positive long-term outlook. Investors looking for stability and growth in the healthcare sector may find ResMed an appealing choice.
- Treasury Wine Estates Ltd (ASX: TWE):
Treasury Wine Estates, a major player in the global wine industry, is another blue-chip ASX share with potential for substantial returns. Analysts at Morgans have given TWE an "Add" rating and set a $14.15 price target, indicating a potential upside of over 30% for investors over the next 12 months.
Morgans is optimistic about Treasury Wine Estates' recent acquisition of DAOU Vineyards, a Paso Robles luxury wine business, for US$900 million. This strategic acquisition aligns with TWE's premiumization and growth strategy, addressing a key gap in its portfolio. DAOU Vineyards is recognized for its solid earnings growth and high-margin business, contributing to TWE's ability to upgrade its margin targets.
The broker acknowledges that the market may take time to digest the sizeable acquisition, given the need for a substantial capital raising. However, Morgans sees the acquisition as a positive move that could deliver significant upside if TWE successfully executes its investment case.
Additionally, Treasury Wine Estates could receive a major boost if China decides to remove tariffs on Australian wine imports. This potential catalyst adds an extra layer of opportunity for investors considering TWE.
In summary, both ResMed and Treasury Wine Estates represent blue-chip opportunities with positive growth prospects. ResMed's leadership in sleep technology and respiratory medicine, coupled with perceived undervaluation, makes it an interesting choice in the healthcare sector. Meanwhile, Treasury Wine Estates' recent strategic acquisition and the potential resolution of tariff issues with China position it well for growth in the wine industry.
Investors should conduct thorough research, consider their risk tolerance, and stay updated on market dynamics before making investment decisions. Analyst recommendations are subject to change based on evolving market conditions and company developments. Past performance is not indicative of future results, and market conditions can change.
